🇺🇸 FDA
Patent

US 8039003

Recombinant attenuated dengue viruses comprising a deletion in the 3′ untranslated region and additional attenuating mutations induced by chemical mutagenesis

granted A61KA61K2039/5252A61K2039/5254

Quick answer

US patent 8039003 (Recombinant attenuated dengue viruses comprising a deletion in the 3′ untranslated region and additional attenuating mutations induced by chemical mutagenesis) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 13 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 18 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 13 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/5252, A61K2039/5254, A61K2039/5256, A61K2039/54